Estimated delivery in United States, on Friday 10 Jan 2025
Product Information
Name:
Tedizolid
Synonyms:
- 2-Oxazolidinone
- 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-
- (5R)-
- (5R)-3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone
- DA 7157
- Sivextro
- TR 700
- (5R)-3-[3-Fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
- (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
- 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-, (5R)-
- See more synonyms
- 3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone
- Da 7157
- Tedizolid Intermediate-8
- Torezolid
- Tr 700
Description:
Applications Tedizolid, known as TR-700, is an oral and i.v administered intracellular antibacterial drug.
References Schaadt, R. et al.: Antimicrob. Agents Chemother., 53, 3236 (2009); Lemaire, S. et al.: J. Antimicrob. Chemother., 64, 1035 (2009)
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
TRC
Long term storage:
Notes:
Chemical properties
Molecular weight:
370.34
Formula:
C17H15FN6O3
Color/Form:
Neat
InChI:
InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
InChI key:
InChIKey=XFALPSLJIHVRKE-GFCCVEGCSA-N
SMILES:
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TR-T013750 Tedizolid
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
